For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
Features:
The conjugation of small proteins, peptides, and oligonucleotides with polyethylene glycol (PEG), or PEGylation, has been shown to improve the pharmacokinetics of biological products by preventing their degradation, as well as improve tissue biodistribution and reducing immunogenicity and toxicity. However, there is an increasing body of data showing that PEG-conjugated compounds elicit IgG and IgM responses and anti-PEG antibodies also occur in 25% of healthy individuals. The presence of circulating anti-PEG antibodies may compromise the immunogenicity and limit the efficacy of therapeutic pegylated compounds. This AlphaLISA kit is designed to accurately measure levels of IgM anti-PEG antibodies in cell culture media, serum, and plasma.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Assay Target | PEG IgM |
---|---|
Assay Target Class | Antibody |
Automation Compatible | Yes |
Detection Method | Alpha |
Experimental Type | In vitro |
Product Brand Name | AlphaLISA |
Shipping Condition | Blue Ice |
Therapeutic Area | Biologics/Bioprocess |
Unit Size | 500 assay points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.